OnDemand

An increasing number of reporting regulations have been introduced and updated at the state level to address the industry trend of ever-increasing Wholesale Acquisition Cost (WAC) prices. As pharmaceutical manufacturers struggle to navigate the patchwork of regulations, a majority are finding it impossible to keep up with existing legislation and the granular details of how to report.

In this informative discussion, John Whitridge and Olivia Nweze break down the current state of drug pricing transparency laws, including price transparency disclosures themes, types of reports, and recent reporting updates for nearly a dozen states including Texas, California, and Oregon.

John Whitridge
Manager, Advisory Services

Olivia Nweze
Senior Consultant, Advisory Services

Learn more by downloading our datasheet detailing solutions to reduce compliance risk around state price transparency reporting.